KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Cash Flow (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Net Cash Flow data on record, last reported at $34.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 136.9% year-over-year to $34.0 million; the TTM value through Dec 2025 reached $129.5 million, up 182.52%, while the annual FY2025 figure was $129.5 million, 182.52% up from the prior year.
  • Net Cash Flow reached $34.0 million in Q4 2025 per IONS's latest filing, down from $41.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $236.3 million in Q4 2021 and bottomed at -$326.5 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$1.3 million, with a median of $27.2 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: plummeted 2065.0% in 2022, then surged 673.14% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $236.3 million in 2021, then plummeted by 116.53% to -$39.1 million in 2022, then skyrocketed by 219.99% to $46.9 million in 2023, then plummeted by 296.35% to -$92.0 million in 2024, then surged by 136.9% to $34.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $34.0 million in Q4 2025, $41.1 million in Q3 2025, and $32.5 million in Q2 2025.